The pharmacokinetics of high dose cyclophosphamide and high dose etoposide.

Abstract

We have studied the pharmacokinetics of single agent high dose cyclophosphamide (HDC) (160-240 mg kg-1) given as repeated intravenous (i.v.) infusions to six patients with small cell lung cancer (SCLC), and HDC (180 mg kg-1) combined with etoposide (750-1000 mg m-2) as repeated i.v. infusions to five patients with SCLC and two patients with teratoma. HDC has a similar pharmacokinetic profile to low dose cyclophosphamide, with a half-life of 4.83 +/- 1.3 h. Repeated administration of HDC produced a small but significant shortening of the half life (P = 0.02). The terminal half-life of high dose etoposide was 7.7 +/- 2 h which is similar to our previous results with low dose etoposide (50-300 mg m-2), but the volume of distribution which was 35.5 +/- 11.6 1. was significantly increased (P less than 0.001). Plasma steady state concentrations of 26.2 +/- 11.7 micrograms ml-1 were achieved. The possible mechanism for the alteration of volume of distribution of etoposide will be discussed.

• Authors: D Cunningham, J Cummings, R B Blackie, L McTaggart, S W Banham, S B Kaye, M Soukop
• Journal: Medical oncology and tumor pharmacotherapy (Med Oncol Tumor Pharmacother) Vol. 5 Issue 2 Pg. 117-23 ( 1988) ISSN: 0736-0118 [Print] England
• PMID: 2842552 (Publication Type: Journal Article)

Chemical References

• Etoposide
• Cyclophosphamide

Topics

• Carcinoma, Small Cell (drug therapy)
• Cyclophosphamide (administration & dosage, pharmacokinetics)
• Drug Therapy, Combination
• Etoposide (administration & dosage, pharmacokinetics)
• Half-Life
• Humans
• Infusions, Intravenous
• Lung Neoplasms (drug therapy)
• Teratoma (drug therapy)